100 results about "Chickenpox" patented technology

The invention belongs to the field of biological medicines, and particularly relates to a varicella-zoster virus gE fusion protein as well as a preparation method and application thereof. The varicella-zoster virus gE fusion protein comprises an amino acid sequence as shown in SEQ ID NO: 1 and at least one of the following fragments: a signal peptide, a Foldon sequence, a Ferritin sequence and a His tag sequence, the signal peptide can improve the protein expression quantity, the Foldon sequence can improve the stability of the protein, the particle size of an antigen can be increased, the immunogenicity of the antigen can be improved, and the fusion protein can be used for preparing a medicine for treating the varicella-zoster virus gE fusion protein. The Ferritin sequence can enhance immune response, a vaccine prepared from the gE fusion protein has excellent immunogenicity, and compared with a commercially available vaccine Shingrix, higher humoral immunity and cellular immunity levels can be induced.

The present application discloses a fusion protein comprising a varicella zoster virus protein and a ferritin, a nucleic acid encoding the fusion protein, a pharmaceutical composition comprising the fusion protein, a method of preparing the fusion protein, and a use of the fusion protein.

The invention provides an anti-varicella-zoster virus monoclonal antibody and an application thereof, relates to the technical field of monoclonal antibody screening and preparation, and more particularly relates to a monoclonal antibody which is obtained by immunizing mice through a recombinant varicella-zoster virus gE trimer protein vaccine. The monoclonal antibody for resisting the varicella-zoster virus is screened and prepared in a hybridoma mode, and the specific application of the antibody is provided. The recombinant VZV-gE tripolymer protein vaccine provided by the invention has good immunogenicity, and can induce higher immune serum titer. The human-mouse chimeric monoclonal antibody disclosed by the invention has good binding activity and affinity to the VZV-gE protein, and the indirect ELISA method for detecting the gE protein has good linear relation and detection limit, so that the human-mouse chimeric monoclonal antibody is expected to be used for VZV vaccine evaluation and VZV infection diagnosis.

The present application provides an RNA encoding a varicella-zoster (VZV) glycoprotein E (gE) or a variant thereof, the RNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence represented by any one of SEQ ID NO: 11-18. The eight mRNAs provided by the invention can translate in cells, the expression level of the generated VZV gE protein is high, and the mRNAs can induce a mouse to generate a high-titer gE specific IgG antibody in a manner of intramuscular injection into the body of the mouse through a preparation formed by encapsulating the lipidosome nanoparticles.

The invention provides a varicella-zoster virus mRNA (messenger Ribonucleic Acid) vaccine and application thereof. The invention firstly provides an mRNA molecule, a coding region sequence of the mRNA molecule comprises a nucleotide sequence for coding an amino acid sequence as shown in SEQ ID NO: 1, and the coding region sequence preferably comprises a nucleotide sequence as shown in any one of SEQ ID NO: 2 to SEQ ID NO: 11, or a nucleotide sequence which has at least 93% similarity with the nucleotide sequence as shown in any one of SEQ ID NO: 2 to SEQ ID NO: 11 and codes the same amino acid sequence. When the mRNA molecule is used for preparing the vaccine, the production cost of the vaccine can be reduced, the physicochemical property of the vaccine is stable, the protein expression is improved to enhance the immune effect of the vaccine, and the humoral immunity and cellular immunity effects of the VZV-gE specificity are enhanced.

The present invention relates to the field of immunology and the field of molecular virology, in particular to the field of prevention and treatment of varicella-zoster viruses. Specifically, the present invention relates to a truncated varicella-zoster virus gE protein (or a variant thereof) capable of be soluble expression in an Escherichia coli expression system, and use thereof in preventing and / or treating varicella-zoster virus infections.

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.

Disclosed are an mRNA vaccine encoding a varicella zoster virus (VZV) protein, a preparation method therefor, and use thereof. The mRNA vaccine is characterized by encoding at least the varicella zoster virus (VZV) gE protein, gH protein, and gL protein.

The invention discloses a varicella zoster vaccine composition and application thereof, and belongs to the technical field of biological vaccines, the composition comprises a VZV gE antigen, a CpG ODN adjuvant and an aluminum adjuvant, and the nucleotide sequence of the CpG ODN adjuvant is shown as SEQ ID NO: 1. According to the invention, the CpG ODN adjuvant with a specific nucleotide sequence is selected, so that the immunostimulatory activity is better; the varicella zoster vaccine composition provided by the invention can generate high humoral immune response earlier, and induces protective immunity for at least one month in advance; the antibody level of twice immunization of a Shigrix vaccine can be reached or close to once immunization, the stable high humoral immune level for a long time can be kept, and meanwhile cellular immunity can be generated.

A preparation method for and the use of an aluminum hydroxide oxide nano-adjuvant based on calcium and silicon doping. The particle morphology of the AlOOH adjuvant is a 50-800 nm nano-particle, wherein silicon or calcium is doped in AlOOH crystal lattices, and the molar ratio of calcium or silicon to aluminum is 0.01-100:1. The preparation method comprises: synthesizing AlOOH by using an Al source, doping Ca or Si in a reaction solution by using a calcium source or a silicon source, precipitating Al(OH)3 and a dopant by adding an alkaline solution, and preparing a Ca- or Si-doped AlOOH adjuvant by means of a hydrothermal synthesis method. In a hepatitis B surface antigen and varicella-zoster virus glycoprotein E antigen model, the calcium- or silicon-doped AlOOH nano-adjuvant can simultaneously induce efficient humoral immunity and cellular immunity by means of in-vivo experiment verification of mice.

A varicella-zoster virus (VZV) nanoparticle protein, and a preparation method therefor and a use thereof. The VZV protein comprises a partial or full sequence of an amino acid sequence of an extracellular region of a VZV gE glycoprotein, with W at position 200 mutation to C and L at position 245 mutation to C in the amino acid sequence of the extracellular region of the VZV gE glycoprotein. By means of the rational optimization design of the amino acid sequence of the VZV gE protein by means of protein genetic engineering, the VZV gE recombinant protein modified with amino acid mutations has increased stability and immunogenicity compared with the VZV gE protein. Moreover, by further designing the protein structure, the VZV gE protein is repeatedly displayed on the surface of ferritin nanoparticles with the desired epitopes exposed, thereby further enhancing immunogenicity.

The invention discloses an mRNA (messenger Ribonucleic Acid) vaccine of varicella-zoster virus as well as a preparation method and application of the mRNA vaccine. According to the mRNA vaccine provided by the invention, a gE antigen sequence is subjected to codon optimization; then selecting a proper promoter, 5 'UTR, 3' UTR and 3 '-terminal PolyA to combine into complete mRNA nucleic acid for coding the varicella-zoster virus, screening to obtain two groups of mRNA nucleic acid for coding the varicella-zoster virus with both expression level and stability, and adopting a novel cationic lipid imidazopyridyl lipid compound to prepare a vaccine liposome. The targeting property in drainage of lymph nodes is improved, and the humoral immunity and cellular immunity levels excited by the vaccine in animal bodies are remarkably improved.

The present disclosure provides immunogenic compositions comprising RSV and VZV antigens, as well as their use in the prevention and / or treatment of VZV and RSV infections.

The invention provides application of sclareol in preparation of a medicine for preventing and treating varicella-zoster virus infection. A series of biological experiments show that the sclareol can obviously relieve the cytopathic effect caused by VZV infection under the concentration without obvious cytotoxicity; the gene expression quantity of VZV characteristic genes including an immediate early gene ORF62, an early gene ORF21 and a late gene ORF68 and the expression of an early protein IE62 and a late protein gE can be remarkably inhibited, so that the effect of resisting VZV infection is achieved. The results show that sclareol has obvious prevention and treatment effects on VZV, has small toxic and side effects, is safe and effective, and has an application prospect in preparation of drugs for treating and / or preventing VZV.

Described are modified Varicella Zoster Virus glycoprotein E (VZV gE) proteins having improved stability and / or immunogenicity compared to a non-modified VZV gE. Also described are associated nucleic acids, immunogenic compositions, and methods of using such modified VZV gE proteins in the treatment or prevention of shingles.

The present disclosure provides methods of inducing an immune response against varicella zoster virus (VZV) in a human subject. The methods provided herein comprise administering to a human subject an immunogenic composition (e.g., a vaccine) comprising an RNA molecule formulated in a lipid nanoparticle. The disclosure also relates to the use of the immunogenic composition for the prevention or treatment of herpes zoster in a human subject.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcal and varicella-zoster virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition. The immunogenic composition of the present invention comprises: at least one pneumococcal polysaccharide-protein conjugate wherein the pneumococcal polysaccharide is linked to a carrier protein through a covalent bond; the carrier protein is varicella-zoster virus glycoprotein E, namely VZV gE recombinant protein, and the amino acid sequence of the VZV gE recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. The immunogenic composition containing the multivalent pneumococcal polysaccharide-protein conjugate, provided by the invention, shows a remarkable synergistic interaction effect, and realizes a'dual enhancement 'effect.

Provided are modified varicella-zoster virus (VZV) gE polypeptide, a circular RNA encoding the modified VZV gE polypeptide, a linear RNA encoding the modified VZV gE polypeptide and the use thereof for inducing an antigen specific immune response in a subject, or preventing or treating VZV infection.

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

A pharmaceutical composition comprising: i) a herpes gE protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two of them; ii) an immunostimulatory composition comprising a saponin and a CpG oligodeoxynucleotide, or consisting of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide. Use of the pharmaceutical composition in the preparation of a medicament for preventing and / or treating a varicella-zoster virus infection and / or a varicella-zoster virus mediated disease. The pharmaceutical composition achieves an unexpected technical effect and can mediate a stronger immune response.

The invention discloses an immunogenic composition containing gE nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biomedicine, the immunogenic composition comprises self-assembled gE nanoparticles and an oil-in-water emulsion adjuvant, and a self-assembled gE nanoparticle antigen comprises gE, a connecting peptide SGS and a gI polypeptide sequence containing Th epitopes; the oil-in-water type emulsion adjuvant is prepared from squalene, Tween 80, DL-alpha-tocopherol and / or Span 85. The immunogenic composition provided by the invention can be applied to vaccines for preventing varicella and / or herpes zoster and / or postherpetic neuralgia, so that the aims of improving the immunogenicity of the gE antigen and reducing side effects of the vaccines are fulfilled.

The invention belongs to the technical field of immunology, and particularly discloses application of 2 ', 3'-cGAMP in preparation of a medicine for enhancing chicken pox-herpes zoster virus vaccine immune response. The 2 ', 3'-cGAMP combined varicella-zoster virus vaccine disclosed by the invention can improve the level of a specific IgG antibody, enhance the cellular immune response intensity of a gE antigen and improve the secretion amount of IFN-gamma and IL-2, so that the immune response of the varicella-zoster virus vaccine is enhanced, the immunoprophylaxis effect is enhanced, and the 2 ', 3'-cGAMP combined varicella-zoster virus vaccine adjuvant can be used for preparing a vaccine adjuvant for treating the varicella-zoster virus. Good application prospects are realized.

The present invention provides a monkey varicella virus TaqMan fluorescent quantitative PCR primer set and application, and relates to the technical field of molecular biology. The present invention uses the conserved region of the monkey varicella virus type 9 genome as the target gene, designs two specific primers and one probe according to the basic principle of TaqMan real-time fluorescent PCR, and establishes a simple, efficient and practical detection method. The monkey varicella virus detection method of the present invention is effective in 10 1 ‑10 11 The sensitivity of the template was 1×10 1 The invention uses TaqMan fluorescent quantitative PCR to accurately quantify monkey varicella virus in real time, which can meet the urgent need of early and accurate clinical diagnosis of monkey varicella virus infection and provide a basis for epidemiological investigation and targeted treatment of monkey varicella virus infection.

The invention discloses a gE fusion protein containing a gH Th epitope and a preparation method and application thereof, and relates to the technical field of biomedicine, the fusion protein comprises a varicella-zoster virus (VZV) glycoprotein E extracellular domain (gE) and a Th epitope-containing VZV glycoprotein H extracellular domain (gH) polypeptide. The gE fusion protein can be applied to VZV vaccines, and solves the technical problems of weak immunogenicity of gE antigens and serious side reaction of vaccines in vaccines prepared in the prior art. Compared with the Xinanlietaine, the vaccine taking the gE fusion protein as the antigen has the advantages that the variety and dosage of immunopotentiators are less, the immunogenicity is better, and the clinical side reaction is lower; besides, the gE fusion protein vaccine not only can induce a gE specific CMI reaction, but also can induce a gH specific CMI reaction, so that the effectiveness of the vaccine is further improved. In short, the gE fusion protein has good clinical application potential.

Provided herein are compositions and methods useful for the detection of herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella zoster virus (VZV). In particular, provided herein are compositions, methods, systems, kits, reagents and reaction mixtures related thereto for nucleic acid amplification and detection procedures for detecting HSV-1, HSV-2, and VZV in a sample.

Various nucleoside phosphate and phosphonate analogues are provided for treatment of viral infections. Methods of preparing the analogues, pharmaceutical compositions containing the analogues, and methods of using the analogues as antiviral compounds, especially against adenoviruses, coronaviruses, and varicella zoster viruses, are also provided.

The present invention provides a genetically recombinant varicella-zoster virus fusion protein and a corresponding preparation method and application. The fusion protein is a fusion protein that utilizes genetic recombination technology to recombinant the amino acid 31-546 (i.e., gE1) of the VZVgE protein in series with a non-toxic toxin carrier protein or its functionally active fragment, and an artificial signal peptide is added to construct a target fusion gene. The target fusion gene is expressed by constructing a recombinant expression vector, transforming, and transfecting CHO cells, and then purifying to obtain a genetically recombinant VZV fusion protein. Compared with simple VZVgE protein, a genetically recombinant VZV fusion protein, especially a genetically recombinant VZV vaccine prepared by combining a genetically recombinant VZV fusion protein with an AS01B adjuvant, can cause higher antibody titers, have better immune activity, and induce stronger cellular immunity, thereby significantly improving the immune-promoting effect of the vaccine, and there is no risk of causing potential infection.

Provided is a varicella zoster vaccine. Specifically, the vaccine comprises an immune composition, and the immune composition comprises an antigen component and a particle protein component. The particle protein component comprises a nanoparticle protein, and the antigen component and the particle protein component covalently bind to each other by means of a binding peptide 1 and a binding peptide 2 to form an immunogenic complex. Provided is a preparation method for the varicella zoster vaccine.